港股異動 | 中生製藥(1177.HK)高開6.96% 擬在科創板上市+獲增持
格隆匯2月4日丨中生製藥(1177.HK)跳空高開6.96%,報8.14港元,暫成交4547萬港元,最新總市值1535億港元。中生製藥昨日晚間發公吿稱,2月3日,董事會已批准可能進行人民幣股份發行並在上交所科創板上市的初步建議。建議境內發行須取決並受限於市況、股東於該公司股東大會上批准以及必要的監管批准。此外,聯交所最新權益披露資料顯示,中生製藥於1月29日獲GIC Private Limited在場內斥資約6883萬港元增持953.8萬股,增持後,其持股比例由4.97%上升至5.02%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.